175 related articles for article (PubMed ID: 12952552)
1. Cost of managing an episode of relapse in multiple sclerosis in the United States.
O'Brien JA; Ward AJ; Patrick AR; Caro J
BMC Health Serv Res; 2003 Sep; 3(1):17. PubMed ID: 12952552
[TBL] [Abstract][Full Text] [Related]
2. Direct medical cost of managing deep vein thrombosis according to the occurrence of complications.
O'Brien JA; Caro JJ
Pharmacoeconomics; 2002; 20(9):603-15. PubMed ID: 12141888
[TBL] [Abstract][Full Text] [Related]
3. Economic and Clinical Burden of Acute Myeloid Leukemia Episodes of Care in the United States: A Retrospective Analysis of a Commercial Payer Database.
Pandya BJ; Chen CC; Medeiros BC; McGuiness CB; Wilson SD; Walsh EH; Wade RL
J Manag Care Spec Pharm; 2020 Jul; 26(7):849-859. PubMed ID: 32281456
[TBL] [Abstract][Full Text] [Related]
4. Societal burden of cluster headache in the United States: a descriptive economic analysis.
Ford JH; Nero D; Kim G; Chu BC; Fowler R; Ahl J; Martinez JM
J Med Econ; 2018 Jan; 21(1):107-111. PubMed ID: 29125368
[TBL] [Abstract][Full Text] [Related]
5. Assessing the direct costs of treating nonvalvular atrial fibrillation in the United States.
Coyne KS; Paramore C; Grandy S; Mercader M; Reynolds M; Zimetbaum P
Value Health; 2006; 9(5):348-56. PubMed ID: 16961553
[TBL] [Abstract][Full Text] [Related]
6. The direct cost of care for psoriasis and psoriatic arthritis in the United States.
Javitz HS; Ward MM; Farber E; Nail L; Vallow SG
J Am Acad Dermatol; 2002 Jun; 46(6):850-60. PubMed ID: 12063481
[TBL] [Abstract][Full Text] [Related]
7. Health Care Burden Associated with Outpatient Opioid Use Following Inpatient or Outpatient Surgery.
Brummett CM; England C; Evans-Shields J; Kong AM; Lew CR; Henriques C; Zimmerman NM; Pawasauskas J; Oderda G
J Manag Care Spec Pharm; 2019 Sep; 25(9):973-983. PubMed ID: 31313621
[TBL] [Abstract][Full Text] [Related]
8. National cost of trauma care by payer status.
Velopulos CG; Enwerem NY; Obirieze A; Hui X; Hashmi ZG; Scott VK; Cornwell EE; Schneider EB; Haider AH
J Surg Res; 2013 Sep; 184(1):444-9. PubMed ID: 23800441
[TBL] [Abstract][Full Text] [Related]
9. Cost effectiveness and budget impact of natalizumab in patients with relapsing multiple sclerosis.
Chiao E; Meyer K
Curr Med Res Opin; 2009 Jun; 25(6):1445-54. PubMed ID: 19422279
[TBL] [Abstract][Full Text] [Related]
10. The economic burden of supportive care of cancer patients.
Elting LS; Shih YC
Support Care Cancer; 2004 Apr; 12(4):219-26. PubMed ID: 14767748
[TBL] [Abstract][Full Text] [Related]
11. The Impact of Price Reductions After Loss of Exclusivity in a Cost-Effectiveness Analysis: Fingolimod Versus Interferon Beta-1a for the Treatment of Relapsing-Remitting Multiple Sclerosis.
Hua LH; Hersh CM; Morten P; Kusel J; Lin F; Cave J; Varga S; Herrera V; Ko JJ
J Manag Care Spec Pharm; 2019 Apr; 25(4):490-498. PubMed ID: 30917079
[TBL] [Abstract][Full Text] [Related]
12. Cost-Effectiveness of Peginterferon Beta-1a and Alemtuzumab in Relapsing-Remitting Multiple Sclerosis.
Dashputre AA; Kamal KM; Pawar G
J Manag Care Spec Pharm; 2017 Jun; 23(6):666-676. PubMed ID: 28530523
[TBL] [Abstract][Full Text] [Related]
13. Rates of hospitalization for asthma by insurance status.
Stanford R; Okamoto L; McLaughlin T
MedGenMed; 2000 Jan; 2(1):E5. PubMed ID: 11104451
[TBL] [Abstract][Full Text] [Related]
14. Estimates of charges associated with emergency department and hospital inpatient care for opioid abuse-related events.
Chandwani HS; Strassels SA; Rascati KL; Lawson KA; Wilson JP
J Pain Palliat Care Pharmacother; 2013 Aug; 27(3):206-13. PubMed ID: 23879214
[TBL] [Abstract][Full Text] [Related]
15. Ectopic pregnancy in the United States: economic consequences and payment source trends.
Washington AE; Katz P
Obstet Gynecol; 1993 Feb; 81(2):287-92. PubMed ID: 8423966
[TBL] [Abstract][Full Text] [Related]
16. Changes in hospital service demand, cost, and patient illness severity following health reform.
Pickens G; Karaca Z; Gibson TB; Cutler E; Dworsky M; Moore B; Wong HS
Health Serv Res; 2019 Aug; 54(4):739-751. PubMed ID: 31070263
[TBL] [Abstract][Full Text] [Related]
17. Burden of illness in patients with possible Lennox-Gastaut syndrome: A retrospective claims-based study.
Reaven NL; Funk SE; Montouris GD; Saurer TB; Story TJ
Epilepsy Behav; 2018 Nov; 88():66-73. PubMed ID: 30241056
[TBL] [Abstract][Full Text] [Related]
18. Cost and utilization of behavioral health medications associated with rescission of an exemption for prior authorization for severe and persistent mental illness in the Vermont Medicaid Program.
Simeone JC; Marcoux RM; Quilliam BJ
J Manag Care Pharm; 2010 Jun; 16(5):317-28. PubMed ID: 20518584
[TBL] [Abstract][Full Text] [Related]
19. Economic model of first-line drug strategies to achieve recommended glycaemic control in newly diagnosed type 2 diabetes mellitus.
Ramsdell JW; Braunstein SN; Stephens JM; Bell CF; Botteman MF; Devine ST
Pharmacoeconomics; 2003; 21(11):819-37. PubMed ID: 12859222
[TBL] [Abstract][Full Text] [Related]
20. Observed costs and health care use of children in a prospective cohort study on community-acquired pneumonia in Geneva, Switzerland.
Keitel K; Alcoba G; Lacroix L; Manzano S; Galetto-Lacour A; Gervaix A
Swiss Med Wkly; 2014; 144():w13925. PubMed ID: 24706389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
